Actively Recruiting
Evaluation of the Artix Thrombectomy System for Treatment of Acute Lower Limb Arterial Occlusions Using a Single-Arm Post-Market Study
Led by Inari Medical · Updated on 2026-10-13
250
Participants Needed
23
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the Artix Thrombectomy System, a device designed for removing arterial blockages in the lower limbs. This study focuses on patients with acute lower limb arterial occlusions occurring below the inguinal ligament, with symptoms lasting 14 days or less. The trial is a post-market, prospective, multicenter, single-arm study sponsored by Inari Medical that aims to gather important data on this treatment approach. Participants receive treatment using the Artix Thrombectomy System to non-surgically remove arterial emboli and thrombi from the lower extremities. This device is used on target lesions in native vessels sized between 3 mm and 8 mm, classified under Rutherford categories I, IIa, or IIb. The study monitors immediate effectiveness after the procedure and safety within 48 hours, with no comparison to other treatments. During the study, participants undergo assessments immediately following treatment and at follow-up visits up to one month later. Researchers will evaluate outcomes such as distal embolization serious adverse events during the procedure, all-cause mortality, limb salvage, and amputation-free survival at one month. Participants are monitored closely to understand the devices performance and safety over the study period, which lasts until October 2029.
CONDITIONS
Brief Title
The ArtixASCEND Study
Research Team
J
James Allen
C
Chris Ottaviano
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here